Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872485 | 0.85 | CRHR1 (0.66) | CRHR1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1235158 | 0.83 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL5872537 | 0.80 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL1236811 | 0.74 | MAPT (0.70) | CRHR1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL16946582 | 0.72 | MAPT (0.69) | CRHR1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23459969 | 0.71 | CRHR1 (0.70) | CRHR1 | |
| SCHEMBL29983877 | 0.71 | CRHR1 (0.70) | CRHR1 | |
| SCHEMBL5730052 | 0.70 | MAPT (0.68) | CRHR1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL23486632 | 0.70 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL5787527 | 0.69 | MAPT (0.62) | CRHR1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-0880523-B1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7074797-B2 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-6664261-B2 | Endocrine, psychiatric and neurologic disorders from hypersecretion of corticotropin-releasing factor | NEUROCRINE BIOSCIENCES, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-0880523-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029109-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885MAPT 3927/4885ALDH1A1 622/4885 |
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | HTR5A, OPRL1, CRHR1 | CRHR1 3/4885MAPT 4265/4885ALDH1A1 397/4885 |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, OPRL1 | CRHR1 1/4885MAPT 3859/4885ALDH1A1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.